This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mohammed, S. I. Articles by Knapp, D. W. Search for Related Content PubMed PubMed Citation Articles by Mohammed, S. I. Articles by Knapp, D. W.

Departments of ¹ Veterinary Pathobiology, ² Basic Medical Sciences, ³ Veterinary Clinical Sciences, and ⁴ Statistics; ⁵ Purdue Cancer Center; ⁶ Center on Aging and the Life Course, Purdue University; and ⁷ The Gerald P. Murphy Cancer Foundation, West Lafayette, Indiana

Requests for reprints: Deborah W. Knapp, Department of Veterinary Clinical Sciences, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026. Phone: 765-494-9900; Fax: 765-496-1108. E-mail: knappd{at}purdue.edu

More than 14,000 people die from invasive transitional cell carcinoma (TCC) of the urinary bladder yearly in the United States. Cyclooxygenase (COX)-inhibiting drugs are emerging as potential antitumor agents in TCC. The optimal in vitro or in vivo systems to investigate COX inhibitor antitumor effects have not been defined. The purpose of this study was to determine COX-1 and COX-2 expression and antitumor effects of COX inhibitors in human TCC cell lines (HT1376, RT4, and UMUC3 cells) and xenografts derived from those cell lines. COX-2 expression (Western blot, immunocytochemistry) was high in HT1376, modest in RT4, and absent in UMUC3 cells in vitro. Similarly, COX-2 expression was noted in RT4 but not UMUC3 xenografts. COX-2 expression in HT1376 xenografts was slightly lower than that observed in vitro. None of four COX inhibitors evaluated (celecoxib, piroxicam, valeryl salicylate, and NS398) reduced TCC growth in standard in vitro proliferation assays at concentrations that could be safely achieved in vivo (5 µmol/L). Higher celecoxib concentrations (50 µmol/L) inhibited proliferation and induced apoptosis in all three cell lines. Celecoxib or piroxicam treatment in athymic mice significantly delayed progression of HT1376 xenografts, which express COX-2, but not UMUC3 xenografts that lack COX-2 expression. In conclusion, standard in vitro assays were not useful in predicting COX inhibitor antitumor effects observed in vivo. Athymic mice bearing TCC xenografts provide a useful in vivo system for COX inhibitor studies. Results of this study provide justification for further evaluation of COX inhibitors as antitumor agents against TCC. [Mol Cancer Ther 2006;5(2):329–36]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/19/05; revised 11/22/05; accepted 12/16/05.

This article has been cited by other articles:

				D. Dhawan, A. B. Jeffreys, R. Zheng, J. C. Stewart, and D. W. Knapp Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells Mol. Cancer Ther., April 1, 2008; 7(4): 897 - 904. [Abstract] [Full Text] [PDF]

				K. M. Rassnick and B. L. Njaa Cyclooxygenase-2 immunoreactivity in equine ocular squamous-cell carcinoma J Vet Diagn Invest, July 1, 2007; 19(4): 436 - 439. [Abstract] [Full Text] [PDF]

				K. E. Eblin, T. G. Bredfeldt, S. Buffington, and A. J. Gandolfi Mitogenic Signal Transduction Caused by Monomethylarsonous Acid in Human Bladder Cells: Role in Arsenic-Induced Carcinogenesis Toxicol. Sci., February 1, 2007; 95(2): 321 - 330. [Abstract] [Full Text] [PDF]

				A. Jimeno, M. L. Amador, P. Kulesza, X. Wang, B. Rubio-Viqueira, X. Zhang, A. Chan, J. Wheelhouse, H. Kuramochi, K. Tanaka, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer Mol. Cancer Ther., December 1, 2006; 5(12): 3240 - 3247. [Abstract] [Full Text] [PDF]